Ancilia Biosciences Announces Closing of $4.2 Million Financing
17 juil. 2024 07h00 HE
|
Ancilia Biosciences
Ancilia raised $4.2M to leverage CRISPR’s natural function to create bacterial therapies with immunity against the viruses that limit their effectiveness.
Caribou Biosciences Announces Appointment of Terri Laufer, MD, to its Scientific Advisory Board
09 juil. 2024 08h00 HE
|
Caribou Biosciences, Inc.
-- Dr. Laufer is an immunologist advancing the scientific understanding and treatment of autoimmune diseases -- BERKELEY, Calif., July 09, 2024 (GLOBE NEWSWIRE) -- Caribou Biosciences,...
SNIPR Biome receives funding for the development of CRISPR-medicines to improve Environmental Enteric Dysfunction (EED) in pregnant women
28 juin 2024 02h50 HE
|
SNIPR BIOME
SNIPR BIOME receives funding from the Bill & Melinda Gates Foundation to accelerate the development of SNIPR Biome's microbial gene therapy platform.
CRISPR and Cas Genes Market Research 2024 - Global Industry Size, Share, Trends, Opportunity, & Forecast, 2019-2029F
20 juin 2024 07h24 HE
|
Research and Markets
Dublin, June 20, 2024 (GLOBE NEWSWIRE) -- The "CRISPR and Cas Genes Market - Global Industry Size, Share, Trends, Opportunity, & Forecast, 2019-2029F" report has been added to ...
Global Genome Editing Market Size, Share & Trends Analysis Report by Technology (CRISPR/Cas9, ZFN), Delivery Method (Ex-vivo, In-vivo) 2024-2030
18 juin 2024 10h19 HE
|
Research and Markets
Dublin, June 18, 2024 (GLOBE NEWSWIRE) -- The "Global Genome Editing Market Size, Share & Trends Analysis Report by Technology (CRISPR/Cas9, ZFN), Delivery Method (Ex-vivo, In-vivo),...
CRISPR Therapies Market Research 2024: Pipeline Analysis, Therapeutic Assessment, Unmet Needs, Impact of Drugs
14 juin 2024 06h15 HE
|
Research and Markets
Dublin, June 14, 2024 (GLOBE NEWSWIRE) -- The "CRISPR therapies - Pipeline Insight, 2024" drug pipelines has been added to ResearchAndMarkets.com's offering.This "CRISPR Therapies - Pipeline...
CRISPR Technology Global Strategic Research Report 2024
14 juin 2024 05h30 HE
|
Research and Markets
Dublin, June 14, 2024 (GLOBE NEWSWIRE) -- The "CRISPR Technology - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.The global market for CRISPR...
Caribou Biosciences Presents Encouraging Clinical Data from CB-010 ANTLER Phase 1 Trial in Second-line LBCL Patients at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
02 juin 2024 19h00 HE
|
Caribou Biosciences, Inc.
-- CB-010 allogeneic CAR-T cell therapy with partial HLA matching has potential to rival efficacy and safety profile of approved autologous CAR-T cell therapies -- -- 14.4 months median PFS in ANTLER...
Caribou Biosciences to Host KOL Discussion with Webcast from the 2024 ASCO Annual Meeting and Participate in Upcoming Investor Conferences
30 mai 2024 16h01 HE
|
Caribou Biosciences, Inc.
BERKELEY, Calif., May 30, 2024 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced the company’s...
Power of Recursion OS on Display at Genome Scale in Nature Genetics Paper Detailing Potential Limitation of CRISPR Gene Editing Tool
29 mai 2024 15h27 HE
|
Recursion Pharmaceuticals
SALT LAKE CITY, May 29, 2024 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today published in Nature...